RYTM in the 13F filings
Rhythm Pharmaceuticals Inc · CUSIP 76243J105
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 28
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 9 listed it in both
- Shares listed
- 9,532,982
- combined, among listed positions
- Reported value
- $1.0bn
- combined, at the quarter end
Among the 92 comparable managers: 16 buyers (opened or added shares) and 16 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +106,756.
Managers listing RYTM in Q4 2025
28 of 28 holders
Largest increases and reductions, by shares
Increases
- Point72 Asset Management LPnew position · 429,420 shares now+429,420
- Capital Research Global Investorsexisting position · 985,086 shares now+386,839
- Wellington Management Group LLPexisting position · 250,156 shares now+225,679
- T. Rowe Price Associates Incexisting position · 1,560,847 shares now+160,950
- Invesco Ltdexisting position · 291,150 shares now+147,595
Reductions
- Fidelity (FMR LLC)existing position · 1,706,317 shares now-438,866
- Voloridge Investment Management LLCexisting position · 60,575 shares now-307,688
- Balyasny Asset Management LLCexisting position · 72,282 shares now-277,726
- Renaissance Technologies LLCexisting position · 341,193 shares now-205,400
- Man Group PLCexisting position · 9,558 shares now-119,772
New positions and exits
New (6)
Exited (4)
- Marshall Wace LLPwas $17m
- Walleye Capital LLCwas $5.1m
- Arrowstreet Capital LPwas $637k
- Quantbot Technologies LPwas $503k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2018 | 1 | $750k | n.a. | n.a. |
| Q2 2018 | 3 | $76m | n.a. | n.a. |
| Q3 2018 | 3 | $91m | n.a. | n.a. |
| Q4 2018 | 1 | $88m | n.a. | n.a. |
| Q1 2019 | 2 | $90m | n.a. | n.a. |
| Q2 2019 | 1 | $72m | n.a. | n.a. |
| Q3 2019 | 1 | $74m | n.a. | n.a. |
| Q4 2019 | 1 | $99m | n.a. | n.a. |
| Q1 2020 | 1 | $66m | n.a. | n.a. |
| Q2 2020 | 1 | $98m | n.a. | n.a. |
| Q3 2020 | 1 | $95m | n.a. | n.a. |
| Q4 2020 | 1 | $134m | n.a. | n.a. |
| Q1 2021 | 1 | $87m | n.a. | n.a. |
| Q2 2021 | 1 | $77m | n.a. | n.a. |
| Q4 2021 | 1 | $593k | n.a. | n.a. |
| Q1 2022 | 1 | $474k | n.a. | n.a. |
| Q2 2022 | 1 | $628k | n.a. | n.a. |
| Q3 2022 | 2 | $43m | n.a. | n.a. |
| Q4 2022 | 1 | $36m | n.a. | n.a. |
| Q3 2023 | 3 | $33m | n.a. | n.a. |
| Q4 2023 | 4 | $61m | 3 | 1 |
| Q1 2024 | 3 | $40m | 2 | 0 |
| Q2 2024 | 4 | $32m | 1 | 3 |
| Q3 2024 | 6 | $80m | 4 | 3 |
| Q4 2024 | 4 | $131m | 4 | 1 |
| Q1 2025 | 4 | $147m | 3 | 1 |
| Q2 2025 | 5 | $160m | 2 | 3 |
| Q3 2025 | 9 | $496m | 7 | 2 |
| Q4 2025 | 10 | $537m | 16 | 16 |
| Q1 2026 | 7 | $450m | 18 | 14 |
| Q2 2026 | 9 | $859m | 14 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RYTM and LLY →RYTM and JNJ →RYTM and VRTX →Choose a stock to compare with RYTM →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RYTM, latest filings →Back to the 13F Explorer →